Literature DB >> 20810290

Experimental evaluation of inhibitory effect of 10-hydroxycamptothecin on hypoxia-inducible factor-1α expression and angiogenesis in liver tumors after transcatheter arterial embolization.

Bin Liang1, ChuanSheng Zheng, GanSheng Feng, HanPing Wu, Yong Wang, Hui Zhao, Xin Li, Jun Qian, HuiMin Liang.   

Abstract

PURPOSE: To evaluate the effect of transcatheter administration of 10-hydroxycamptothecin (HCPT), a hypoxia-inducible factor-1α (HIF-1α) inhibitor, on HIF-1α expression and angiogenesis in liver tumors after transcatheter arterial embolization in an animal model.
MATERIALS AND METHODS: VX2 tumors were implanted in the livers of 30 rabbits. The animals were divided randomly into three groups of 10 animals each. Group 1 animals received hepatic intraarterial infusion of distilled water. Group 2 animals received iodized oil infusion followed by embolization with 150-250 μm of polyvinyl alcohol particles. Group 3 animals received infusion of a mixture of HCPT (1 mg/kg body weight) with iodized oil followed by the particle embolization. Six hours or 3 days after transcatheter treatment, the animals were sacrificed, and the tumor samples were harvested. Immunohistochemical staining was performed to evaluate the levels of HIF-1α and vascular endothelial growth factor (VEGF) protein as well as microvessel density.
RESULTS: The levels of HIF-1α and VEGF and microvessel density in tumors of group 2 were significantly higher than those of group 1 or 3 (P < .05). However, no significant differences were noted in tumors between group 1 and 3 (P > .05). HIF-1α levels were significantly correlated with VEGF levels (r = .587, P = .001) and microvessel density (r = .527, P = .003).
CONCLUSIONS: Transcatheter infusion of HCPT has an inhibitory effect on HIF-1α expression and angiogenesis in liver tumors after transcatheter arterial embolization.
Copyright © 2010 SIR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20810290     DOI: 10.1016/j.jvir.2010.05.028

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  5 in total

1.  Radiofrequency ablation-induced upregulation of hypoxia-inducible factor-1α can be suppressed with adjuvant bortezomib or liposomal chemotherapy.

Authors:  Marwan Moussa; S Nahum Goldberg; Gaurav Kumar; Rupa R Sawant; Tatyana Levchenko; Vladimir Torchilin; Muneeb Ahmed
Journal:  J Vasc Interv Radiol       Date:  2014-10-16       Impact factor: 3.464

Review 2.  Rabbit VX2 Liver Tumor Model: A Review of Clinical, Biology, Histology, and Tumor Microenvironment Characteristics.

Authors:  Florentina Pascale; Jean-Pierre Pelage; Michel Wassef; Saïda H Ghegediban; Jean-Pierre Saint-Maurice; Thierry De Baere; Alban Denys; Rafael Duran; Frédéric Deschamps; Olivier Pellerin; Noboru Maeda; Alexandre Laurent; Julien Namur
Journal:  Front Oncol       Date:  2022-05-10       Impact factor: 5.738

3.  Rational design of temperature-sensitive blood-vessel-embolic nanogels for improving hypoxic tumor microenvironment after transcatheter arterial embolization.

Authors:  Ling Li; Yiming Liu; Han Li; Xiaopeng Guo; Xiaojun He; Shinan Geng; Hao Zhao; Xiaole Peng; Dingwen Shi; Bin Xiong; Guofeng Zhou; Yanbing Zhao; Chuansheng Zheng; Xiangliang Yang
Journal:  Theranostics       Date:  2018-11-29       Impact factor: 11.556

4.  Early Assessment of Response to Radiofrequency Ablation With CT Perfusion Imaging in Rabbit VX2 Liver Tumor Model.

Authors:  Xiaofei Yue; Xiangjun Dong; Mengting Huang; Hongli Yang; Kun Qian; Changhong Yi; Osamah Alwalid; Yanqiao Ren; Ping Han; Qian Li
Journal:  Front Oncol       Date:  2021-11-25       Impact factor: 6.244

Review 5.  The role of hypoxia inducible factor-1 in hepatocellular carcinoma.

Authors:  Dongjun Luo; Zhongxia Wang; Junyi Wu; Chunping Jiang; Junhua Wu
Journal:  Biomed Res Int       Date:  2014-07-02       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.